This is an updated version of a survey first published in April 2001, covering offers by pharmaceutical companies and generic manufacturers of discounted prices for antiretroviral drugs.
To print this table, we recommend that you select `Landscape` mode by going to Print in your browser and then select `Preferences` in Internet Explorer or `Properties` in Netscape, and adjust the print mode to `Landscape` in the Orientation section.
|
Generic name
|
Brand Name
|
Initials
|
Manufacturer
|
Discount Price (on standard dose unless stated)
|
Special provisions
|
Generic Alternative (Country/manufacturer name) style='font-family:Verdana'>
|
|
|
Protease inhibitors
|
|||||||
|
Lopinavir style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>/ritonavir
|
Kaletra
|
N/a
|
Abbott
|
c.$650per year Further cuts promised
|
(available to private sector or company health plans and NGOs, as well as govts)
|
None
|
|
|
Ritonavir
|
Norvir style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Abbott
|
c. $650 Further cuts promised
|
(available to private sector or company health plans and NGOs, as well as govts)
|
India (Hetero - c. $4300 p.a.)
|
|
|
Nelfinavir
|
Viracept style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Roche
|
$1800 p.a
|
Sub-Saharan style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(Hetero - $2248 p.a.)
|
|
|
Saquinavir
|
Fortovase style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Roche
|
c. $670 for SQV when dosed at 1800mg qd with ritonavir 100mg c.$800 when dosed at 100mg/100mg twice daily
|
Sub-Saharan style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(Hetero - $992 p.a.)
|
|
|
Indinavir
|
Crixivan style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Merck
|
$600 per year
|
Romania
(Available to NGOs and company health plans, as well as govts)
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>:
|
|
|
CIPLA - $2300 p.a at 800mg tid)
|
|||||||
|
Ranbaxy: Virodin
|
|||||||
|
Hetero – Indivir ($1840 p.a. at 800mg tid)
|
|||||||
|
|
|||||||
|
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
|
|||||||
|
Nevirapine
|
Viramune
|
|
Boehringer Ingelheim
|
Free as two doses for mother and infant treatment $1.22 per day for adult dosing ($445 p.a)
|
Maternal/infant treatment free to all non-EU countries (also excludes style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>USA style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Canada style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, NZ, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Australia style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Japan style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Switzerland style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Norway style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>, style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>Iceland style='font-size:9.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>)
|
Nevirapine has been patented in 25 African countries style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>: class=SpellE>Cipla p.a. to non-profits)
|
|
|
Ranbaxy: Nevipan
|
|||||||
|
Hetero: Nevivir
|
|||||||
|
Efavirenz
|
Stocrin style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Merck
|
$500 per year
|
Africa Romania Haiti Brazil ($846 pa) (Available to NGOs and company health plans, as well as govts)
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(Aurobindo $485 p.a)
|
|
|
|
|||||||
|
Nucleoside analogues (NRTIs)
|
|||||||
|
Stavudine
|
Zerit
|
D4T
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> Myers
Squibb
|
15 cents a day/$54 per year for dose applicable to adults 60kg and over; lower cost applies at lower body weight
|
Not available to private sector/company health plans
|
Note: Stavudine is not patented in any African country except style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>: class=SpellE>Cipla $40 p.a to non-profits)
|
|
|
Ranbaxy: Virostav
|
|||||||
|
Hetero/Genix Pharma: style='mso-bidi-font-style:normal'>Stag
|
|||||||
|
Thailand
|
|||||||
|
Brazil
|
|||||||
|
Didanosine style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
Videx style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
DdI style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> Myers
Squibb
|
80 cents per day/ $310 p.a. for dose applicable to adults 60kg and over; lower cost applies at lower body weight
|
Not available to private sector/company health plans
|
Note: Didanosine is not patented in any African country except style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>South
Africa
|
|
|
Thailand: non-buffered version Brazil
|
|||||||
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(CIPLA - $584; Aurobindo $190 p.a)
|
|||||||
|
Zidovudine and lamivudine
|
Combivir
|
AZT and 3TC
|
Glaxo Smith Kline
|
$2 per day ($730 p.a)
|
Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDS Accelerating Access Initiative
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(CIPLA - Duovir $554 pa to
non-profits
|
|
|
Ranbaxy style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> – class=SpellE>Virocomb style='mso-spacerun:yes'>
|
|||||||
|
Zidovudine
|
Retrovir
|
AZT
|
Glaxo Smith Kline
|
95% reduction on "average global price"
|
As above
|
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
(CIPLA: Zidovir $306 p.a lang=NL style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;
mso-ansi-language:NL'>
|
|
|
Ranbaxy: style='mso-bidi-font-style:normal'>Viro-2
|
|||||||
|
Hetero: Zido-H
|
|||||||
|
Abacavir style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
Ziagen style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
N/a
|
Glaxo Smith Kline
|
|
As above
|
|
|
|
Lamivudine
|
Epivir
|
3TC
|
Glaxo Smith Kline
|
58 cents per day
|
As above
|
Note: Lamivudine is patented in 33 African countries
|
|
|
CIPLA - style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>India style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> (Lamivir, 30 cents per day to non-profits)
|
|||||||
|
Hetero/GenixPharma: style='mso-bidi-font-style:normal'>Heptavir
|
|||||||
|
Ranbaxy: Virolam
|
|||||||
|
Zalcitabine style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
Hivid style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
ddC style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
Roche
|
Available at cost
|
|
Brazil
|
|
|
|
|||||||
|
Combinations
|
|||||||
|
Lamivudine, zidovudine and nevirapine
|
|
AZT, 3TC and nevirapine
|
CIPLA
|
$350 p.a
|
Non-profits (Govts $600 p.a)
|
Note: each component of this combination is patented in 23 African countries
|
|
|
Aurobindo style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'> ( style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>India style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>)
|
$295 p.a
|
Offered to govt health progs
|
|||||
|
Lamivudine, stavudine and nevirapine
|
|
3TC, d4T and nevirapine
|
Hetero (India)
|
$350 p.a
|
Offered to govt health progs
|
Note : style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
stavudine dose within these formulations is 40mg bid – lower doses for lower
body weight have not been announced.
|
|
|
Ranbaxy lang=FR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;
mso-ansi-language:FR'> (India) – style='mso-bidi-font-style:normal'>Virolans 30 style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana'>
|
$388 (295 p.a to MSF and NGOs)
|
||||||
|
General Pharmaceutical Organization (Thailand) lang=FR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Verdana;
mso-ansi-language:FR'>
|
$324 p.a
|
||||||